title: Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Basak Oven
authors.initials: BO
authors.lastname: Ustaalioglu
authors.forename: Tarik
authors.initials: T
authors.lastname: Salman
authors.forename: Berkant
authors.initials: B
authors.lastname: Sonmez
authors.forename: Nesrin A
authors.initials: NA
authors.lastname: Canpolat
authors.forename: Taflan
authors.initials: T
authors.lastname: Salepci
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yaylaci
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab